Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00042666 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00042666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00042666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2002
Completion date
September 30, 2008
Enrollment
55 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma